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Abstract
Background
Osteosarcoma is an orphan disease for which little improvement in survival has been made
since the late 1980s. New drug discovery for orphan diseases is limited by the cost and time
it takes to develop new drugs. Repurposing already approved FDA-drugs can help over-
come this limitation. Another limitation of cancer drug discovery is the lack of preclinical
models that accurately recapitulate what occurs in humans. For OS using dogs as a model
can minimize this limitation as OS in canines develops spontaneously, is locally invasive
and metastasizes to the lungs as it does in humans.
Methods
In our present work we used high-throughput screens to identify drugs from a library of
2,286 FDA-approved drugs that demonstrated selective growth inhibition against both
human and canine OS cell lines. The identified lead compound was then tested for synergy
with 7 other drugs that have demonstrated activity against OS. These results were con-
firmed with in vitro assays and an in vivo murine model of OS.
Results
We identified 13 drugs that demonstrated selective growth inhibition against both human
and canine OS cell lines. Auranofin was selected for further in vitro combination drug
screens. Auranofin showed synergistic effects with vorinostat and rapamycin on OS viability
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and apoptosis induction. Auranofin demonstrated single-agent growth inhibition in both
human and canine OS xenografts, and cooperative growth inhibition was observed in com-
bination with rapamycin or vorinostat. There was a significant decrease in Ki67-positive
cells and an increase in cleaved caspase-3 levels in tumor tissues treated with a combina-
tion of auranofin and vorinostat or rapamycin.
Conclusions
Auranofin, alone or in combination with rapamycin or vorinostat, may be useful new treat-
ment strategies for OS. Future studies may evaluate the efficacy of auranofin in dogs with
OS as a prelude to human clinical evaluation.
Introduction
Osteosarcoma (OS) represents the most common malignant bone tumor with a bimodal peak
in adolescents and in those greater than 60 years of age [1]. Overall survival increased signifi-
cantly between 1973 and 1993, but since that time 5-year survival percentages have remained
stagnant at about 60 percent [1]. Attempts have been made to improve survival by the addition
of cytotoxic chemotherapy to the traditional backbone of therapy, most recently ifosfamide
and etoposide. In patients that had over 10% viable tumor at time of primary tumor resection,
additional treatment with ifosfamide and etoposide had no improvement in event free survival
[2, 3]. New strategies are needed to expediently move new treatments into the clinical setting
that work synergistically with other agents known to effectively treat OS.
OS is classified as an orphan disease as it affects only approximately 800 patients per year in
the United States. The cost of new drug discovery for orphan diseases is often prohibitive for
pharmaceutical companies [4]. One option to overcome this issue is to repurpose already
FDA-approved drugs. We previously demonstrated that non-profit collaborators can advance
repurposed FDA-approved drugs to patients much faster and at lower cost than new chemical
entities [5]. Furthermore, we showed that drug repurposing opportunities can be rapidly and
efficiently achieved in an academic setting [6].
As with drug discovery, the lack of preclinical models that accurately recreate what occurs
in humans and serve as effective tools in predicting therapeutic response in cancer patients is a
challenge for investigators pursuing drug repurposing [7]. In the case of OS, however, nature
provides a model that closely resembles humans. About 10,000 canines a year spontaneously
develop OS [8]. There are several similarities between human and canine OS including that it
usually involves the limbs, is locally invasive and metastasizes to the lungs [9, 10]. Moreover,
metastasis is the major cause of death for both human and canine OS. Indeed, ~80% of canine
OS patients demonstrate lung metastasis within six months of limb amputation [11], thus giv-
ing translational scientists a great model with rapid read out on drug activity [12]. Finally,
comparative studies have demonstrated striking similarities in gene expression between canine
and human OS [13].
Here, we employed a comparative oncology approach to drug repurposing in OS. We
evaluated an extensive library of FDA-approved drugs for anticancer activity in validated
human and canine OS cell lines in parallel. From these studies, auranofin (Ridaura1), a FDA-
approved oral agent for the treatment of rheumatoid arthritis, was selected for testing its effi-
cacy to suppress OS growth in tissue culture and nude mice, as well as for showing synergistic
effects with agents potentially effective in OS therapy. Intriguingly, auranofin had cooperative
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effects with vorinostat and rapamycin. Our study will advance to a future proof of principle
study in canine OS patients and furthermore serve as the rationale for advancing auranofin to
human clinical proof of concept studies.
Material and methods
OS cell lines
The following cell lines were maintained in Dulbecco’s Modified Eagle’s Medium (DMEM)
with 10% fetal bovine serum (FBS) and 1% penicillin-streptomycin: human skin fibroblasts BJ
(p53wt), human osteoblast hFOB 1.19 (p53wt), human OS KHOS/NP (p53R156P), Saos2-LM7
(p53null), MG-63 (p53null), and mouse fibroblasts NIH/3T3 (p53wt) were obtained from
ATCC, human osteoblasts NHOst (p53wt) were obtained from Lonza, canine OS Abrams
(p53R237W,C265F), and D17 (p53wt) were obtained from Douglas H. Thamm (Colorado State
University, USA). All cell lines used were authenticated [14–16].
FDA-approved drug library
The compound management system within the University of Kansas High Throughput
Screening (HTS) Laboratory contains 2,286 FDA-approved drugs sourced from Enzo (640
drugs), NIH (446 drugs) and Prestwick (1,200 drugs) compound collections. Compounds are
stored at a concentration of 10 mM in dimethyl sulfoxide (DMSO). This library is routinely
screened for activity in validated cell-based and biochemical high-throughput screening assays
supporting multiple projects, the results of which are contained in an integrated database.
Primary screen
The cells were plated in 384-well microplates at the following densities: hFOB 1.19 (5,000 cells/
well), MG-63 and KHOS/NP (3,000 cells/well), and Abrams (4,000 cells/well), D17 (8,000
cells/well). Each of the 2,286 FDA-approved drugs was transferred to the 384-well assay plates
acoustically using Echo 555 (Labcyte) at a final concentration of 2.5 μM. Media and vehicle
control wells were included in each assay plate. After 48 hours incubation at 37˚C, cytotoxicity
was measured on Enspire plate reader (Perkin Elmer) using the luminescence-based CellTiter-
Glo reagent (Promega Inc.). All plates included DMSO (0.025%) controls (n = 16). The Z’
scores of five independent screens were>0.7, indicating a good separation of maximum and
minimum signals. The Z’ score of>0.5 indicates suitability of the assay for compound screen-
ing. Approximately 40 FDA-approved drugs were cytotoxic (defined as>50% inhibition of
viable cell proliferation) in some or all of canine and human OS cell lines screened. Thirteen of
the FDA-approved drugs that are not used for human or canine OS therapy were selected for
further study. These drugs were repurchased as fresh powders and tested for growth inhibition
after 48 hours at multiple concentrations across the four human and canine OS cells lines as
well as control non-tumor cell lines (hFOB, NIH/3T3, and NHOst) using CellTiter-Glo.as
above. The approximate inhibitory concentration at 50% maximal growth inhibition (IC50) for
each cell line was calculated. For those FDA-approved drugs demonstrating concentration-
response, a drug development and regulatory science gap analysis was performed. Drug repur-
posing opportunities were ranked or prioritized based on: 1) the opportunity to achieve ade-
quate systemic drug exposure following well-tolerated OS patients based on drug-drug
interaction potential with current standard-of-care agents; 2) having acceptable safety profile
associated with systemic drug administration; and 3) current drug product label supporting
rapid translation of the agent to OS patients. Auranofin demonstrated an in vitro IC50 value
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ranging from 0.7 to 2.4 μM in all OS cell lines tested. In humans auranofin can achieve steady
state mean blood gold levels that approximate 3.5 μM [17].
Drug combination screens
Doxorubicin, methotrexate, rapamycin, valproic acid, vorinostat, cisplatin, and etoposide were
selected for in vitro studies applied in combination with auranofin. These seven agents were
selected based on their clinical significance as agents are currently used in the upfront treat-
ment of pediatric and canine OS or have demonstrated promising pre-clinical or early phase
clinical trial data. In vitro IC50 values were determined for each of the seven agents individually
by determining cytotoxicity over 48 hours of exposure in MG-63 cells, a well characterized,
aggressive human OS cell line, using CellTiter-Glo cell viability assays (S1 Fig). The concentra-
tion of each agent observed at 50% maximal growth inhibition in 48 hours served as a guide-
line for defining concentrations of each agent applied in combination with auranofin. Each
384-well plate contained two 11X 14 concentration-matrix blocks, with serial dilutions for aur-
anofin on the X-axis and for these drugs along the Y-axis.
Drug synergy evaluation
The growth inhibition of each drug alone was first used to identify Highest Single Agent
(HSA). GraphPad Prism software (GraphPad Software; Inc, La Jolla, CA) was used to charac-
terize the drug-drug interaction using Bliss independence (combination effect is independent
from the action of second agent: Fa+Fb-FaFb), and Chou-Talalay-based Calcusyn software
was used to generate concentration-response curves, median-effect plots and a normalized iso-
bolograms. The median effect plots linearize all concentration-effect curves that follow mass
action law principle and were calculated from equation: fa/fu = (D/Dm)m, where fa is the frac-
tion of cells affected by drug, fu is the fraction of cells unaffected by drug, D is the drug con-
centration, Dm is the median-effect concentration and m is the slope or kinetic order. The
combination index (CI) for each two drug interactions was defined using the following equa-
tion: CI = (D)1/(Dm)1[fa/1-fa]
1/m1 + (D)2/(Dm)2[fa/1-fa]
1/m2, where CI (< 1, = 1 and>1,
indicate synergism, additive effect, and antagonism, respectively). The slopes generated by Cal-
cusyn were used to generate normalized isobologram to identify combination data points that
fall in the lower left (synergism), on the hypotenuse (additive) or on upper right of the line
(antagonism).
Cell counting assays
This assay was performed to further validate the effects of auranofin on inhibiting proliferation
of multiple OS cell lines with minimal effects on that of non-tumor cells. Cells were seeded onto
6-well plates (10,000–30,000 cells per well depending on the cell line, day 0). Twenty-four hours
after seeding, cells were treated with 2 different concentrations of DMSO (control) or aurano-
fin. Live cell numbers were counted at days 2, 4, 6, 8, and 10, following trypan-blue staining.
Western blotting
Western blotting for PCNA, cleaved caspase-3 and vinculin or GAPDH (control) in KHOS/
NP and Abrams cell lines was performed in order to examine the effects of auranofin and its
combination with vorinostat and rapamycin on their protein expression. KHOS/NP and
Abrams cell lines were chosen due to their aggressive behaviors and abilities to cause meta-
static disease. Both cell lines contain mutations in the p53 gene [18, 19]. Cells were lysed with
radioimmunoprecipitation assay (RIPA) buffer containing phosphatase and protease
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inhibitors (EMD Chemicals). Cell lysates containing 20–100 μg protein was loaded onto
4–20% tris-glycine gel (Bio-Rad Laboratories, Inc.), separated by electrophoresis, transferred
to polyvinylidene fluoride (PVDF) membrane (GE Healthcare Life Sciences), blotted with pri-
mary antibodies against specific proteins, and appropriate secondary antibodies conjugated
with fluorophores. All blots were analyzed with the LI-COR Odyssey infra-red imaging sys-
tems (Lincoln, Nebraska). The following antibodies were used: PCNA (PC-10; Santa Cruz
Biotechnology), vinculin (10R-C105a, Fitzgerald), Cleaved-caspase-3 (D3E9; Cell Signaling
Technology), GAPDH (FL-335; Santa Cruz Biotechnology), IRDye 680RD goat anti-rabbit
IgG, and IRDye 800CW goat anti-mouse IgG (LI-COR).
Propidium iodide (PI) staining and flow cytometry
In order to examine the effects of auranofin and its combination with vorinostat and rapamy-
cin on cell cycle profiles of OS cells, we performed PI-staining and flow cytometry analysis.
Cells were fixed overnight with 70% ethanol at -20˚C and stained with PI solution (Life Tech-
nologies) in the presence of 62 μg/ml of RNase A, followed by flow cytometric analysis using
BD Accuri flow cytometer (BD biosciences, San Jose, CA). Data was analyzed using the FlowJo
V10 software (FlowJo LLC, Ashland, Oregon).
Mice and in vivo tumor growth assay
To perform proof-of-principle studies toward application to canine and human OS clinical
investigation, we examined effects of auranofin and its combination with vorinostat or rapa-
mycin on in vivo OS growth in nude mice. All mice were purchased from Envigo and were
maintained under specific-pathogen-free conditions with regular diet. All experimental proce-
dures were conducted in accordance with the institutional animal welfare guidelines of the
University of Kansas Medical Center and we obtained approval from the University of Kansas
Medical Center Institutional Animal Care and Use Committee (IAUCUC #2013–2167). Cells
(1X106) were subcutaneously injected into 6-week-old female nude-Foxn1nu mice. During
injections, mice were gently held and monitored closely for signs of pain or distress. When
these signs were noted, the mice were released and the procedure was stopped. When tumors
became 3mm in diameter, DMSO, auranofin (0.1 mg/kg), vorinostat (2.5 mg/kg), and rapamy-
cin (0.1 mg/kg), as well as the combination of auranofin with vorinostat or rapamycin were
intraperitoneally injected 5 days per week for 3 weeks. Tumor sizes were measured three-
dimensionally twice per week during 21 days [20]. Mice were carefully monitored daily with
body condition score. When tumors reached approximately 1.5 cm in diameter or mice
became moribund, had greater than 20% weight loss or showed <2 for the body conditioned
score, they were euthanized utilizing carbon dioxide followed by bilateral thoracotomy.
Immunohistochemistry (IHC)
After 21 days of treatment with DMSO, auranofin (0.1 mg/kg), vorinostat (2.5 mg/kg), and
rapamycin (0.1 mg/kg), as well as the combination of auranofin with vorinostat or rapamycin
the tumor tissues were harvested, sectioned at 4 μm, and subjected to IHC by standard proce-
dures. Briefly, sections from the aforementioned tumor tissues were deparaffinized in xylene,
rehydrated in grades of alcohol, rinsed in tap water and blocked with 0.3% hydrogen peroxide
for 30 min. Antigen retrieval was performed in a steamer with sodium citrate buffer (10 mM
sodium citrate, pH 6.0) for 20 min. After blocking in 2.5% normal horse serum for 30 min, sec-
tions were incubated with anti-Ki67 (ab15580, 1:2500; Abcam), and anti-cleaved caspase-3
(D3E9, 1:500) for 30 min at room temperature. After washing in PBS, sections were incubated
in biotinylated secondary antibody for 30 min. The signal was detected using the Vectastain
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Elite ABC kit (Vector Laboratories). Pre-immune serum and normal rabbit IgG (Vector Labs,
Burlingame) were used as negative controls.
Statistical analysis
The differences in cell proliferation, percentages of sub-G0/G1 population, and tumor growth
between different treatments were analyzed by two-tailed Student’s t-tests with GraphPad
Prism 5 (GraphPad Software, Jolla, CA). Statistical significance was set at p< 0.05, unless oth-
erwise stated in the text.
Results
Primary screening of FDA-approved library identifies auranofin as a
potential drug that reduces viability of OS cells
To identify whether a currently marketed drug contained within our compound library of
2,286 FDA-approved drugs could suppress growth of human and canine OS cells, we per-
formed high-throughput cell viability assays using 2 human (KHOS/NP and MG-63) and 2
canine (D17 and Abrams) OS cell lines, as well as hFOB human osteoblast cell line as a control
(S1 Table). Forty drugs showed significant growth suppression as single agents. Thirteen of the
40 drugs identified demonstrated concentration-response relationships resulting in measur-
able IC50 values in human and canine OS cell lines (Fig 1A, Table 1). Auranofin (Ridaura
1)
demonstrated an in vitro IC50 value ranging from 0.7 to 2.4 μM in all of OS cell lines tested
(Fig 1B). We selected auranofin for further in vitro combination drug screens based on the
following observations: 1) our previous study evaluating auranofin in chronic lymphocytic leu-
kemia patients (NCT01419691) which demonstrates mechanisms of action relevant to the
treatment of OS [21], 2) in vitro synergistic anticancer activity in combination with other phar-
macologic classes of anticancer agents [22], 3) the fact that the current marketed Ridaura1
drug product could be readily administered to human and canine OS patients.
We then performed long-term cell proliferation assays by treating 4 aggressive human OS
cell lines (MG-63, Saos2-LM7, KHOS/NP, Abrams) and two non-transformed mouse and
human fibroblast cell lines (NIH/3T3 and BJ, respectively) with 0.2 μM or 0.5 μM of auranofin
(lower than IC50 values). Auranofin again showed specificity on OS cell lines to suppress their
growth, compared with non-transformed fibroblast cell lines (Fig 2).
Auranofin shows synergistic effects with vorinostat and rapamycin on
viability of MG-63 cells
To examine whether auranofin shows cooperative effects with other chemotherapy agents that
are currently used for OS treatment or have demonstrated a potential to treat OS in preclinical
studies, we treated MG-63 cells with auranofin along with 7 chemotherapy agents, including
doxorubicin, methotrexate, rapamycin, valproic acid, vorinostat, cisplatin, and etoposide, at
various concentrations to determine combination indices. Of these, vorinostat and rapamycin
demonstrated synergistic effects with auranofin, as shown in Fig 3A and 3B, respectively.
Thus, hereafter we decided to examine the combinatory effects of auranofin with vorinostat or
rapamycin.
Combination of auranofin with vorinostat or rapamycin synergistically
induces apoptosis in OS cells
To address the potential mechanism by which auranofin shows cooperative effects on viability
of OS cells with vorinostat or rapamycin, we performed propidium-iodide (PI) staining and
Comparative oncology approach to drug repurposing in osteosarcoma
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flow cytometry analyses following treatment of two metastatic OS cell lines KHOS/NP and
Abrams with low concentrations (0.5 μM of vorinostat or 1 μM of rapamycin) of these drugs
in the absence or presence of 1 μM of auranofin (~50% of IC50) for 24 hours [8, 18, 23]. Co-
treatment of vorinostat or rapamycin with auranofin significantly increased sub-G0/G1 sub-
population of the cell cycle in KHOS/NP cells, as compared with that with auranofin alone
(Fig 4A, left). Similar results were obtained using Abrams cell line (Fig 4A, right). We also con-
firmed an increase in the expression of cleaved caspase-3 and a decrease in PCNA expression
in both KHOS/NP and Abrams cells (Fig 4B). These results suggest that combination of aura-
nofin with vorinostat or rapamycin cooperatively induce apoptosis in KHOS/NP and Abrams
cell lines in vitro.
Fig 1. Primary screening of FDA-approved library identifies auranofin as a potential drug for OS therapy. A. A diagram of the primary screening
to select auranofin. B. Auranofin chemical structure (top) and concentration-response curves of auranofin cytotoxic effects on human (MG-63 and
KHOS/NP) and canine (Abrams and D17) OS cells (bottom). Graph also includes IC50 values for each cell line. Error bars: means ± S.D. from
3-independent experiments.
https://doi.org/10.1371/journal.pone.0194224.g001
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Auranofin, in combination with vorinostat or rapamycin, significantly
reduces tumor growth of KHOS/NP and Abrams cells in mice
We next attempted to examine combinatory effects of these drugs on in vivo tumor growth.
KHOS/NP and Abrams cells were subcutaneously injected into nude mice. When tumors
reached 3 mm in diameter, mice were intraperitoneally injected with DMSO or auranofin
(AF, 0.1 mg/kg) and/or vorinostat VST, (2.5 mg/kg) or rapamycin (RPM, 0.1 mg/kg) 5 days
per week for 3 weeks. Tumor sizes were measured twice per week. Combinations of auranofin
with either vorinostat or rapamycin significantly suppressed tumor growth of KHOS/NP
cells as compared with single treatments of these drugs (Fig 5A and 5B). Similar results were
obtained with Abrams cells (Fig 5C and 5D). During the course of experiments, all three drugs
used were well tolerated by tumor-bearing nude mice at doses described above. Moreover,
immunohistochemistry analyses using KHOS/NP-tumors revealed that there was significant
decrease in Ki67-positive cells and increase in cells positive for cleaved caspase-3 in tumors
treated with these drug combinations, as compared with those with DMSO (control) and sin-
gle-agent treatments (Fig 5E). These results demonstrate cooperative effects of auranofin with
vorinostat or rapamycin on the inhibition of in vivo OS growth.
Discussion
In this study, we demonstrate auranofin’s ability to inhibit OS cell growth at an IC50 that is
achievable in murine models and can be translated into an IC50 that is achievable in humans.
Auranofin (Ridaura 1) is an oral gold complex that is FDA-approved to treat rheumatoid
arthritis [24]. It has demonstrated activity in multiple different cancer cell lines including gas-
trointestinal stromal tumor (GIST) [4], Ewing sarcoma [25], chronic lymphocytic leukemia
(CLL) [21], Hodgkin lymphoma [26], and ovarian cancer [27]. Auranofin’s ability to inhibit
thioredoxin reductase is one of the main mechanisms by which it causes cancer cell death [25,
28, 29]. Cancer cells generate more reactive oxygen species than normal cells, and therefore
they are more dependent upon the systems that regulate the oxidative stress [30, 31]. Thiore-
doxin reductase is a major cellular anti-oxidant protein [32], and hence by inhibiting this
enzyme more oxidative stress occurs in cells. Thus, increased oxidative stress could be a possi-
ble mechanism underlying auranofin-induced OS cells death.
Table 1. FDA-approved compounds that show inhibition of osteosarcoma cell proliferation.
Compound Cytotoxicity (% of control)
KHOS/NP MG-63 D17 Abrams
10-Hydroxycamptothecin 82.0 58.0 34.9 66.8
Cerivastatin 72.1 82.3 91.1 74.4
Disulfiram 22.7 8.9 51.8 49.4
Ciclopirox ethanolamine 35.8 20.5 25.4 40.0
Dequalinium dichloride 17.2 35.2 32.2 9.9
Puromycin 95.1 90.2 93.8 70.7
Quinacerine 47.5 28.7 21.7 21.2
Auranofin 70.2 44.4 72.7 86.4
Alexidine dihydrochloride 53.8 38.6 41.0 32.0
Cytarabine 26.4 32.6 15.7 4.4
Antimycin A-HCl 32.8 27.5 48.4 42.1
Amantidine 14.1 23.4 10.6 21.3
Novobiocin a-Na 19.5 26.3 20.7 27.1
https://doi.org/10.1371/journal.pone.0194224.t001
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One of the major challenges for successfully treating cancer patients is cancer’s resistance to
chemotherapy which can be present at time of initial diagnosis or develop over time with treat-
ment [33]. One way to overcome this resistance is to administer drugs that work synergistically
[34]. Here, we showed that auranofin has potential synergistic effects with vorinostat and
Fig 2. Auranofin preferentially reduces viable cell proliferation of OS cells with minimum effects on non-tumor cells. Mouse and human
fibroblast, (NIH/3T3 and BJ, respectively; control; 3x104) as well as human OS cells (Saos2-LM7, MG-63, KHOS/NP, and Abrams; 1x104) were
treated with two different concentrations of auranofin (0.2 μM and 0.5 μM) 24 hours after seeding, and the numbers of alive cells were counted
every 48 hours for 10 days following trypan blue staining. DMSO was used as a vehicle control. Graphs show numbers of cells on days following
treatment with auranofin. Error bars: means ± S.D. from 3 independent experiments. , P< 0.05; , P< 0.01; Student’s t test. NS: not significant.
https://doi.org/10.1371/journal.pone.0194224.g002
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rapamycin. Vorinostat is an inhibitor of histone deacetylases (HDACs), a group of enzymes
which are involved in epigenetic modification and interact with multiple transcription factors
such as p53 and NF-kB [35]. HDAC inhibitors have demonstrated the ability to decrease OS
cell migration in vitro, inhibit growth of human OS cells, and induce cell cycle arrest both in
vitro and in mouse models [36–38]. Rapamycin is an inhibitor of mammalian target of rapa-
mycin (mTOR), a serine/threonine kinase that plays roles in the signaling to a variety of down-
stream kinases [38]. In murine model of metastatic OS, rapamycin decreases the development
of pulmonary metastasis by inhibition of the mTOR/S6K1/4E-BP-1 pathway [39]. Inhibition
of this pathway is also found to decrease cell motility [40]. mTOR and its downstream signal-
ing are also found to be effective targets for canine OS cells [41]. Penel-Page et al. [42] report
that in patients given rapamycin (sirolimus) alone or in combination with other medications,
10 out of the 23 patients have stabilization of disease with 3 maintaining complete remission.
Everolimus, also an mTOR inhibitor, in combination with sorafenib, is used to treat patients
with relapse or unresectable OS [43]. Even though this study does not meet the target of 6
months progression-free survival (PFS) of 50% or greater, some patients achieve prolonged
Fig 3. Auranofin shows synergistic effects with vorinostat and rapamycin on the viability of MG-63 cells. MG-63 cells were treated with various
concentrations of auranofin along with vorinostat (A) or rapamycin (B) for 48 hours, and the cytotoxicity was determined. Representative Bliss
independence plots are shown on the left. Summaries of all combination indices (numbers) calculated by Chou-Talalay plots using data obtained from
varying combination pairs of auranofin and vorinostat or rapamycin (right).
https://doi.org/10.1371/journal.pone.0194224.g003
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Fig 4. Combination of auranofin with vorinostat or rapamycin synergistically induces apoptosis in KHOS/NP and Abrams cells. (A)
PI-staining and flow cytometry analysis following treatments of KHOS/NP (left) and Abrams (right) cells with DMSO (control), auranofin,
vorinostat (VST), rapamycin (RPM), or indicated combinations for 48 hours. Representative results of cell cycle profiles (top) and a
summarized graph showing % of sub-G0/G1 population of the cell cycle following indicated drug treatments (bottom). Error bars:
means ± S.D. from three independent experiments. , P< 0.01; Student’s t test. (B) Representative images of western blotting for cleaved
caspase-3 and PCNA, as well as vinculin or GAPDH as loading controls, using whole protein extracts from KHOS/NP (left) and Abrams
(right) cells treated with DMSO, auranofin (1 μM), vorinostat (VST, 0.5 μM), and/or rapamycin (RPM, 1 μM) for 24 hours.
https://doi.org/10.1371/journal.pone.0194224.g004
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Fig 5. Auranofin, in combination with vorinostat or rapamycin, significantly reduces tumor growth of KHOS/NP and Abrams
cells in mice. A-D. Tumor formation assays in nude mice subcutaneously injected with KHOS/NP (1X106 (A, B) or Abrams (1.5X106
(C, D)) OS cells. When tumors reached 3 mm in diameter, mice were intraperitoneally injected with DMSO or auranofin (AF), along
with vorinostat (VST (A, C), or rapamycin (RPM (B, D). Tumor sizes were three-dimensionally measured twice a week. Graphs
showing sizes of tumors formed in mice (top). Note that the results of DMSO and auranofin alone in (C) were also used in (D), since
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stabilization of disease/partial response. Currently there are 2 open clinical trials recruiting
patients with osteosarcoma to receive metronomic chemotherapy which includes sirolimus;
NCT02517918 and NCT02574728. Of note there is currently an open phase I/II trial evaluating
the combination of auranofin and sirolimus in adult patients with advanced lung cancer
(NCT01737502) providing further evidence that this combination is of clinical interest.
Our in vivo studies also showed that there was suppression of OS tumor growth with each
drug alone, but tumor growth was significantly inhibited when auranofin was given in combi-
nation with either vorinostat or rapamycin. The doses of drugs used in this study were less
than those administered in previous studies with other cell lines [21, 39, 44]. Along with sup-
pression of tumor growth, there was also a significant decrease in Ki67-positive cells (consis-
tent with decrease in cell proliferation) and increase in cleaved caspase-3 levels in tumor
tissues when treated with combination of auranofin and vorinostat or rapamycin, further sup-
porting the synergism between auranofin and vorinostat or rapamycin. The mechanisms
behind their synergism need to be further elucidated.
The major reason we evaluated FDA-approved drugs in both human and canine OS cell
lines was to capitalize on canines as a model for OS. OS in canines demonstrates many similar-
ities to human OS [45]. Canines are also treated with local control measures and chemotherapy
[46–48]. As in humans, OS in dogs demonstrates high metastatic ability, and the majority of
dogs die due to lung metastasis [48]. Currently, evaluation of auranofin in canine cancer
patients is on-going in a phase 1 trial to assess the maximum tolerated dose of auranofin in
this population. The ultimate goal of our research is to lead to combination therapy with aura-
nofin and vorinostat or rapamycin in human OS patients.
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